![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 38, 35978-35989, September 21, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, January 18, 2001, and in revised form, June 11, 2001
Although several cardiac-specific transcription
factors have been shown to play vital roles in various steps during the
heart formation, the precise mechanism of the early stage of
cardiogenesis has yet to be elucidated. By differential display
technique, we tried to identify molecules that are expressed earlier
than cardiac transcription factors such as CSX/NKX2-5 and GATA-4 and
are involved in cardiomyocyte differentiation using the P19CL6 cell
line, which efficiently differentiates into cardiomyocytes when treated
with dimethyl sulfoxide. We isolated a novel gene designated
Midori. Its deduced amino acid sequence contained an
ATP/GTP-binding site, Ig-like domain, and Kringle-like domain. Northern
blot analysis revealed that expression of Midori was
restricted to the fetal and adult heart and adult skeletal muscle in
mice. In whole mount in situ hybridization,
Midori was expressed in cardiac crescent and developing
heart but not in somites. The MIDORI protein was localized in the
nucleus and overexpression of Midori induced expression of
endogenous Midori itself, suggesting that MIDORI may act as
a transcriptional regulator. Permanent P19CL6 cell lines
overexpressing Midori more efficiently differentiated into cardiomyocytes than did parental cells, whereas those overexpressing the antisense Midori less efficiently differentiated. These
results suggest that Midori may promote the differentiation
of P19CL6 into cardiomyocytes.
Recent genetic studies have demonstrated that several
heart-enriched transcription factors play vital roles in various
developmental steps during the formation of the heart. Among them,
CSX/NKX2-5, GATA-4, and MEF2C have been well characterized and used as
early lineage-specific molecular markers of cardiac development.
Csx/Nkx2-5 is a murine cardiac homeobox gene that was
originally identified as a potential vertebrate homolog of
Drosophila tinman (1, 2). Csx/Nkx2-5 is
predominantly expressed in the heart and in cardiac progenitor cells
from the early developmental stage. The heart does not form at all in
the tinman mutant of Drosophila (3), and the
development of the heart stops at the looping stage in
Csx/Nkx2-5 knockout mice (4). In humans, it has been reported that patients with familial atrial septal defect or other congenital heart diseases have point mutations in the human
CSX/NKX2-5 gene in one allele (5-7). Gata-4 and
Mef2c are also thought to be involved in the early
stage of cardiogenesis (8-10). Both of them started to be expressed in
the precardiac mesoderm almost simultaneously with
Csx/Nkx2-5. A zinc finger transcription factor, GATA-4 has
been reported to be necessary for differentiation of the pluripotent
P19 embryonal carcinoma cells into beating cardiomyocytes. In this
system, the inhibition of Gata-4 expression by antisense transcripts interferes with the differentiation of the P19 cells at the
precardiac (cardioblast) stage (11). In contrast, the ectopic
expression of Gata-4 in P19 cells accelerates cardiogenesis (12). In vivo bilateral cardiac primordia fail to fuse at
the ventral midline in Gata-4 Although characteristics and functions of these cardiac transcription
factors have been well studied, the precise molecular mechanism of the
earlier stage of cardiac development, i.e. the mechanism by
which these transcription factors themselves are regulated, remains
largely unknown at present. It has recently been reported that some
growth factors play an important role in initial induction of cardiac
differentiation. For example, decapentaplegic
(dpp) and bone morphogenetic proteins, which are the
members of the transforming growth factor- In the investigation of the molecular mechanisms of cardiomyocyte
differentiation, in vitro culture systems present a great advantage in contrast to the complexity in analyzing them in the in vivo situation. In the present study, we used the P19CL6
in vitro cardiomyocyte differentiation system. P19CL6 is a
clonal derivative isolated from murine P19 embryonal carcinoma cells by
the limiting dilution method (18). Unlike P19 cells (19, 20), whose use
is limited because of their quite low efficiency of differentiation
into cardiomyocytes, this CL6 subline efficiently (more than 80%)
differentiates into beating cardiomyocytes with adherent conditions
when it is treated with 1% dimethyl sulfoxide (Me2SO) (13, 18). Expression of cardiac-specific
transcription factors such as CSX/NKX2-5, GATA-4, and MEF2C and
contractile protein genes such as myosin heavy chain
(MHC)1 and myosin light chain
2v (MLC2v) are detected from day 6 and from day 10, respectively (13),
whereas skeletal muscle-specific transcripts such as myogenin and
MyoD are not detected throughout the differentiation of the
cells (18), suggesting that myocytic differentiation of this cell line
induced by Me2SO treatment is purely cardiogenic. On the
other hand, P19CL6 cells can differentiate into neurons and other
neuroectodermal derivatives by treatment with retinoic acid (18).
Because these observations suggest that this subline of P19 is not
committed into cardiac precursor cells nor even into mesoderm before
induction of differentiation, P19CL6 is a useful model for studying the
molecular mechanism by which the very early stage of cardiac
specification is induced.
Using the differential display technique in this P19CL6 system, we
isolated a novel gene named Midori, representing
Myocytic induction/differentiation
originator, in the present study. Expression of
Midori was restricted to the developing heart from the very early stage of cardiogenesis. The MIDORI protein was localized in the
nucleus, and overexpression of Midori induced expression of
endogenous Midori itself, suggesting that MIDORI may act as a transcriptional regulator. Overexpression of Midori
enhanced the differentiation ability of P19CL6 cells into
cardiomyocytes, whereas inhibition of Midori suppressed it.
These results suggest that Midori may promote the
differentiation of P19CL6 into cardiomyocytes.
Cell Culture and Differentiation--
P19CL6 cells were cultured
essentially as described previously (18). Briefly, the cells were grown
in a 100-mm tissue culture dish under adherent conditions with
RNA Extraction and Analysis--
Total RNA was extracted by the
acid guanidine method (RNA Zol B, TEL-TEST, Inc.), and Northern blot
analysis was performed with 20 µg of total RNA as follows. Total RNA
was subjected to 1% agarose/formaldehyde gel electrophoresis and
subsequently transferred onto a Hybond-N membrane filter (Amersham
Pharmacia Biotech). Hybridization was carried out in 50% formamide,
5× saline/sodium phosphate/EDTA, 5× Denhardt's solution, 5%
dextran sulfate, and 0.5% SDS at 42 °C overnight. The probe was
labeled with [32P]dCTP by random priming (Takara).
Differential mRNA Display and Subcloning of Reamplified
cDNA Fragments--
Differential display was performed with an
RNAmap kit (Genhunter Co.) as described previously (21-25) for 0.8 µg each of total RNA from day 0 and day 6 of P19CL6 cells. cDNA
bands present in the day 6 lane and absent in the day 0 lane were
extracted, reamplified, and subcloned into the TA cloning vector
pCR II (Invitrogen). The plasmids were digested with EcoRI
and electrophoresed on a 2.0% agarose gel. The inserts were
extracted from the gel (QIAEX II Gel Extraction Kit, Qiagen) and
labeled as described above for Northern blot analysis. If the same
expression pattern was obtained in the Northern blot on P19CL6,
Northern blot analysis on fetal (17.5 days postcoitus (dpc)) and
adult (8 weeks old) mice was performed.
P19CL6 Day 6 cDNA Library Synthesis--
About 20 µg of
poly(A)+ RNA of P19CL6 day 6 was separated from 1 mg of
total RNA after selecting twice through oligo(dT)-cellulose type 7 (Amersham Pharmacia Biotech), and 5 µg of poly(A)+ RNA
was used to synthesize a cDNA library using a ZAP-cDNA
synthesis kit and ZAP-cDNA Gigapack III Gold cloning kit
(Stratagene). This manipulation yielded a library consisting of
2.88 × 106 independent clones.
cDNA Library Screening and DNA Sequencing--
Using the
cDNA fragment obtained from the differential screening,
Midori was isolated from the P19CL6 day 6 cDNA library
prepared as described above. Plasmids were excised from phage vectors
in vivo by ExAssist helper phage and were subjected to
sequencing with Big Dye Terminator and ABI PRISM 310 (PerkinElmer Life
Sciences) using ordinary sequencing primers and four custom-synthesized primers as follows: P1, 5'-TACTCCATGCCAGGTCTCAAG-3'; P2,
5'-GATGGAGAGGCAAACAAGGCT-3'; P3, 5'-TGTTCTGGATCTTGCATCCCT-3'; P5,
5'-GACTCAAGCCAGTTGAATGCC-3'. We also used a mouse skeletal muscle
5'-STRETCH PLUS cDNA library (CLONTECH)
to get the full length of Midori. Phage DNA was purified from isolated clones (Lambda DNA miniprep, Qiagen), digested with EcoRI, and subcloned into pBluescript II SK+
(Stratagene). The clones were sequenced and analyzed using the BLAST
sequence analysis program.
Whole Mount in Situ Hybridization
Analysis--
Pregnant females of mouse strain ICR were killed by
cervical dislocation on 7.5-10.5 dpc. Harvested mouse embryos were
fixed in 4% paraformaldehyde, phosphate-buffered saline (pH 7.4) and treated with 10 µg/ml proteinase K at 37 °C for 3 min. Then
samples were incubated with 2 mg/ml glycine, with 0.2% glutaraldehyde, 4% paraformaldehyde, and with 0.1% sodium borohydride subsequently. Digoxigenin (DIG)-labeled cRNA probes were synthesized with in vitro transcription using a DIG RNA labeling kit (Roche Molecular Biochemicals). A part of the cDNA of Midori (not
shown) was used for the template of the antisense and sense
ribonucleotide probes, and that of MLC2v (not shown) was used for the
template of the antisense probe as a positive control for
hybridization. Hybridization was done with 2 µg/ml DIG-labeled cRNA
probes in 50% formamide, 750 mM sodium chloride, 1 mM EDTA, 10 mM PIPES, 1% SDS, 100 µg/ml yeast tRNA, 0.05% heparin, and 0.1% bovine serum albumin at 63 °C
overnight. After washing with a low concentration of salt, the RNase
reaction was carried out with 100 µg/ml RNase A and 100 units/ml
RNase T1 in 0.5 M sodium acetate, 10 mM PIPES,
and 0.05% Tween 20. Samples were washed and incubated with a 2000× dilution of anti-DIG alkaline phosphatase conjugate (Roche
Molecular Biochemicals) at 4 °C overnight. Then mRNA-cRNA
hybrids were detected by staining with BM Purple alkaline phosphatase
substrate (Boehringer Mannheim) at room temperature for 1 h for
the MLC2v probe and for 2-3 h for the others.
Transfection of Tagged cDNA and Immunochemical
Staining--
Two kinds of epitope-tagged cDNAs of
Midori in the expression vector were constructed. The
HA-pcDNA3 vector was digested and ligated with the open reading
frame of Midori to make a HA-tagged MIDORI protein with a
6-amino acid deletion of MIDORI at the amino terminus. Similarly,
pcDNA3.1( Stable Transformants--
Midori cDNA of either
sense or antisense orientation was subcloned into pEFSAneo, which
harbors the human elongation factor 1- Immunofluorescence--
Immunostaining with MF20, a monoclonal
antibody against a sarcomeric MHC, was performed on day 8 of
differentiation by using anti-mouse immunoglobulin G conjugated with
tetramethyl rhodamine isothiocyanate as the secondary antibody. We
chose day 8 because thereafter most cells differentiate into
cardiomyocytes and are MF20-positive in both P19CL6 and the
Midori-overexpressing cell lines, and therefore it might be
hard to show the difference among these cell lines.
Protein Extraction and Western Blot Analysis--
Total protein
of the cell lines on day 14.5 of differentiation was extracted using
cell lysis buffer containing 25 mM Tris-HCl (pH 7.4), 25 mM sodium chloride, 0.5 mM EGTA, 10 mM sodium pyrophosphate, 1 mM orthovanadate, 10 mM sodium fluoride, and 10 nM okadaic acid. The
equal volume of cell lysate was subjected to 5% polyacrylamide gel electrophoresis and subsequently transferred onto a Hybond-ECL membrane filter (Amersham Pharmacia Biotech). MF20 and anti-mouse immunoglobulin G conjugated with horseradish peroxidase were
incubated as the first and the second antibody, respectively, in
Tris-buffered saline (pH 7.6) containing 0.1% Tween 20. After washing
in this buffer, the filter was soaked in ECL Western blotting detection reagents (Amersham Pharmacia Biotech) for 45 s, and subsequently the autoradiogram was developed after a 30-s exposure.
Cloning of the Muscle-specific Midori cDNA--
To isolate
novel molecules expressed in the very early stage of cardiac
development, we performed the differential display method using the
P19CL6 cell line as an in vitro model for cardiomyocyte differentiation. Because expression of cardiac transcription factors such as CSX/NKX2-5, GATA-4, and MEF2C are detected on day 6 (6 days
after the initiation of Me2SO treatment) in P19CL6 cells (13), we compared mRNA extracted from the differentiating cells of
day 6 and from the undifferentiated cells of day 0 (i.e.
before the Me2SO treatment). We obtained several
differentially expressed cDNA fragments that were detected on day 6 but not on day 0. These cDNA fragments were therefore thought to
represent parts of genes whose expression was induced in the early
stage of differentiation. Among them, a fragment primarily amplified
using the prepared primers in the RNAmap kit, AP5 and T12MA, was
denoted as 5A1 (Fig. 1). Northern blot
analysis using the 5A1 fragment as a cDNA probe revealed that the
transcripts represented by 5A1 were detected as a single
~6.4-kilobase pair band abundantly on days 4 and 6 and faintly
thereafter but not at all on day 0 (Fig. 2A), indicating that the mRNA expression was induced by the treatment with
Me2SO and preceded expression of cardiac transcription
factors such as CSX/NKX2-5, GATA-4, and
MEF2C. Such temporal expression patterns imply the possibility that this molecule represented by the 5A1 fragment might play an important role in cardiomyocyte differentiation of P19CL6 at the relatively early developmental stage. We next examined
tissue distribution of this mRNA using 20 µg of total RNAs from
various tissues of fetal and adult mice. Northern blot analysis
revealed that the expression was restricted to the heart of fetal mice
and to the heart and skeletal muscle of adult mice among the various
organs examined, suggesting that expression of this gene was
myocyte-specific (Fig. 2, B and C). We screened the originally prepared cDNA library of P19CL6 day 6 and a random and oligo(dT)-primed cDNA library of murine skeletal muscle using the subcloned band as a probe and obtained a corresponding cDNA ~6.4 kilobases in length. It contained the Kozak consensus sequence (26) in the 5'-region and ~5-kilobase pair open reading frame. A
polyadenylation signal was situated at 32 base pairs upstream of the
poly(A) tract. Two Ig-like C2-type domains, several nuclear localization signals, a proline/alanine-rich region, an ATP/GTP-binding site, and a Kringle-like domain were present in the deduced amino acid
sequence (Fig.
3).
Considering these results and its possible functions as described
below, we designated this novel gene Midori representing
Myocytic
induction/differentiation
originator.
Expression of Midori in Murine Embryos--
To examine the precise
spatial and temporal expression pattern of Midori in mouse
embryogenesis, whole mount in situ hybridization was
performed. Murine embryos at 7.5, 8.5, 9.5, and 10.5 dpc were prepared
and hybridized with Midori sense and antisense and MLC2v antisense ribonucleotide probes. The probes were synthesized using DIG-labeled UTP. The Midori expression was first detected in
the cardiac crescent at 7.5 dpc when the developing heart became
visible and continued through 10.5 dpc. The expression of
Midori was localized within the heart at least until 10.5 dpc as well as that of MLC2v used as a positive control (Fig.
4). Although Northern blot analysis revealed that Midori was abundantly expressed in the
skeletal muscle of adult mice (Fig. 2C), the expression was
not detected in somites where differentiation into skeletal
muscle took place. These results suggest that Midori is
expressed specifically in the heart from the very early stage of
cardiac development also in vivo.
Nuclear Localization of the MIDORI Protein in Transfected COS
Cells--
The existence of a nuclear localization signal in the amino
acid sequence of MIDORI protein (Fig. 3) suggested its localization in
the nucleus. To examine the intracellular localization of MIDORI, HA-
and Myc-tagged MIDORI were separately transfected into COS cells.
Immunochemical staining with both anti-HA and anti-Myc antibodies
revealed that the MIDORI protein was expressed only in the nucleus
(Fig. 5).
Blockade of Midori Expression Inhibited the Differentiation of
P19CL6 into Cardiomyocytes--
To elucidate the role of
Midori in cardiac differentiation, we isolated the stable
P19CL6 cells that overexpressed the antisense Midori and
examined the differentiation ability of the cells. Three independent
neomycin-resistant clones containing the Midori antisense
sequence were isolated, and two of them (designated as A1 and A2, Fig.
6) were differentiated and analyzed.
Expression of the Midori antisense sequence had no effect on
the morphology and the proliferative ability of the undifferentiated
cells (data not shown). When treated with Me2SO, however,
the cell line A1, which expressed antisense transcripts more abundantly
than A2 (Fig. 6, large arrowhead), differentiated much less
efficiently than A2 and parental P19CL6 cells. In P19CL6 and antisense
cell lines, some parts of the cells formed aggregations (Fig.
7, A and B,
arrowheads) that were not immunostained by MF20 and did not
beat at all. More aggregations were observed in A1 than in A2 (Fig.
7A). More MF20-positive beating foci were seen at day 8 in
A2 than in A1 (Fig. 7B, stained in red). In
Western blot analysis on day 14.5 of differentiation, a lesser amount
of MHC protein was detected in the line A1 than in A2 and P19CL6 (Fig. 7C, arrow). Overall, the antisense cell line
contained less MF20-positive areas at day 8 of differentiation and less
MHC protein at day 14.5 than did parental P19CL6 cells, suggesting that
inhibition of Midori partially blocked cardiomyocyte
differentiation of P19CL6 in a dose-dependent manner.
Overexpression of Midori Up-regulated Expression of Endogenous
Midori and Enhanced the Ability of P19CL6 to Differentiate into
Cardiomyocytes--
We next performed gain-of-function experiments by
overexpressing Midori in P19CL6 cells. Five independent
neomycin-resistant clones that stably overexpressed Midori
were isolated, and two of them (designated as S1 and S2, Fig. 6) were
differentiated and analyzed. Midori-overexpressing cells did
not show any morphological difference with wild-type P19CL6 cells when
cultured without Me2SO (data not shown). However, unlike in
wild-type P19CL6 cells, mRNA levels of endogenous
Midori (Fig. 6, arrow) were more abundant than
those of exogenous Midori (Fig. 6, large
arrowhead) in the undifferentiated cells, suggesting that
expression of Midori was induced by itself. When treated
with Me2SO, Midori-overexpressing P19CL6 cells
differentiated into cardiomyocytes more efficiently than did wild-type
P19CL6. Highly aggregated noncardiomyocytes seen in wild-type or in the
antisense cell lines were only weakly detected in the
Midori-overexpressing cell lines (Fig. 7A).
Immunocytochemical staining of MHC on day 8 of differentiation (Fig.
7B, stained in red) and Western blot analysis of
MHC on day 14.5 (Fig. 7C, arrow) revealed that
the Midori-overexpressing cells more efficiently differentiated into cardiomyocytes than did parental P19CL6 cells, suggesting the potential role of Midori in the induction of
cardiomyocyte differentiation.
Cardiac-specific transcription factors such as CSX/NKX2-5, GATA-4,
and MEF2C have recently been clarified to play important roles in the
formation of the heart. These cardiac transcription factors are
critical regulators of normal cardiac development and are useful
molecular markers to examine effects of inductive signals from other
tissues or germ layers. However, little is known about the genetic
cascades that induce expression of these transcription factors
themselves in the earlier stage of cardiac development. Therefore, we
tried to identify transcriptional regulators that exist upstream of
these cardiac transcription factors and control their expression using
the P19CL6 in vitro culture system and obtained several
results as follows. (i) We isolated a novel myocyte-specific gene
Midori that was expressed earlier than cardiac transcription
factors such as CSX/NKX2-5, GATA-4, and MEF2C in P19CL6 cells. (ii)
Expression of Midori was localized in the primitive heart in
early embryogenesis and was detected in cardiac and skeletal muscle in
the adult mice. (iii) The MIDORI protein was localized in the nucleus
and induced by Midori itself. (iv) Overexpression of
Midori enhanced the differentiation of P19CL6 into
cardiomyocytes, whereas the blockade of Midori expression
inhibited it.
The cDNA sequence of Midori revealed that MIDORI
contained two Ig-like C2-type domains (Fig. 3,
boxed), several nuclear localization signals (Fig. 3,
underlined), a proline/alanine-rich region (Fig. 3,
dotted-underlined), an ATP/GTP-binding site motif A (Fig. 3, bold), and a Kringle-like domain (Fig. 3,
broken-underlined). Transfection experiments using the
epitope-tagged cDNA of Midori revealed that the MIDORI
protein was localized in the nucleus and that exogenous
Midori induced expression of endogenous Midori itself in undifferentiated P19CL6 cells, suggesting its possible role
as a transcriptional regulator. Several transcription factors contain
proline-rich regions, which are known to act as transactivation or
repression sites (27, 28). Vascular endothelial growth factor receptor
(29-32) and platelet-derived growth factor receptor (33, 34)
have regions homologous with the Ig-like domain of MIDORI. These
domains consist of a heparin- or agonist-binding site and are thought
to be essential for receptor dimerization. Hepatocyte growth factor
contains domains similar to the Kringle-like domain of MIDORI. This
domain is necessary for receptor binding (35-38). No other
nucleus-localized genes with these motifs have been reported to date,
and possible interactions with other transcription factors and the
transactivating/repressing ability of this novel gene have yet to be investigated.
To elucidate the physiological roles for Midori in
cardiomyocyte differentiation, we performed transfection experiments to enhance or inhibit the function of Midori in P19CL6 cells.
Stable transfectants overexpressing the Midori antisense
cDNA failed to differentiate into cardiomyocytes by the treatment
with Me2SO, whereas those overexpressing the sense cDNA
more efficiently differentiated into cardiomyocytes than did the
wild-type P19CL6 cells. During the process of differentiation, many
dead cells were observed in the Midori-overexpressing cell
lines, and the nuclei of these cells were condensed and terminal dUTP
nick-end labeling (TUNEL)-positive (data not shown). These
findings were also observed in the wild type but to a smaller extent,
and only a few cells died in the antisense cell lines (data not shown).
The fact that forced expression of Midori did not harm
undifferentiated P19CL6 cells nor COS cells and that the surviving
cells in the Midori-overexpressing cell lines efficiently
differentiated into cardiomyocytes suggest the possibility that
Midori might induce the apoptosis of noncardiomyocytes during the differentiation of P19CL6 cells. Further studies are necessary to prove this hypothesis.
Recently another group cloned a part of a potential human homolog of
Midori. The cDNA fragment, designated KIAA1330, was
cloned from human brain but was expressed mainly in the heart and
skeletal muscle (39) as we showed in mice (see Fig. 2C). The
genomic locus was assigned to human chromosome 15 (39). KIAA1330
contains an ~2.7-kilobase pair open reading frame
corresponding to the 3'-part of the open reading frame of
Midori. In the 3' part of the open reading frame, the
amino acid sequence of MIDORI is 74% identical and 79% homologous to
that of KIAA1330. However, no information about the function of this
gene is available at present.
Here we have first demonstrated potential important roles of this novel
gene in cardiomyocyte differentiation. Further investigation of the
precise molecular functions of MIDORI will provide new insights into
the understanding of the complicated mechanisms of heart development.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dept. of Cardiovascular
Science and Medicine, Chiba University Graduate School of Medicine,
1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. Tel.: 81-43-226-2097;
Fax: 81-43-226-2557; E-mail: komuro-tky@umin.ac.jp.
Published, JBC Papers in Press, June 19, 2001, DOI 10.1074/jbc.M100485200
The abbreviations used are:
MHC, myosin heavy
chain;
MLC2v, myosin light chain 2v;
dpc, days postcoitus;
DIG, digoxigenin;
PIPES, 1,4-piperazinediethanesulfonic acid;
HA, hemagglutinin.
A Novel Myocyte-specific Gene Midori
Promotes the Differentiation of P19CL6 Cells into Cardiomyocytes*
,
,
,
,
, and
**
Department of Cardiovascular Medicine,
University of Tokyo Graduate School of Medicine, Tokyo 113-8655, the
§ Department of Medicine I, Shinshu University, School of
Medicine, Matsumoto 390-8621, the ¶ International Medical Center
of Japan, Tokyo 162-8655, and the
Department of Cardiovascular
Science and Medicine, Chiba University Graduate School of Medicine,
Chiba 260-8670, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice (8, 9). MEF2C is a
member of MADS-box transcription factors, and targeted disruption of Mef2c results in right ventricular dysplasia (10).
Thus, Drosophila TINMAN, CSX/NKX2-5, GATA-4, and MEF2C are
critical regulators of cardiac development and are useful molecular
markers for examining effects of inductive signals from other tissues
or germ layers.
superfamily, have been
shown to be important candidates that regulate expression of some
cardiac-enriched transcription factors such as TINMAN, CSX/NKX2-5, and
GATA-4 and induce cardiomyocyte differentiation. We previously
demonstrated that bone morphogenetic proteins are indispensable
for cardiomyocyte differentiation and that bone morphogenetic proteins
induce cardiomyocyte differentiation through cardiac transcription
factors CSX/NKX2-5 and GATA-4 (13). As well as bone morphogenetic
proteins/dpp, other growth factors such as
Wnt/wingless (14) and fibroblast growth factors (15-17) have been reported to be essential for normal cardiac development. However, the precise molecular cascades from these growth factors to
cardiac-specific genes needed for cardiac specification have yet to be
elucidated. From this respect, we tried to identify molecules that are
expressed in precardiac cells earlier than cardiac-specific
transcription factors and to clarify the molecular mechanism by which
induction of cardiac differentiation is controlled.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-minimal essential medium (Life Technologies, Inc.) supplemented
with 10% fetal bovine serum (JRH Bioscience), penicillin (100 units/ml), and streptomycin (100 µg/ml) (growth medium) and were
maintained in a 5% CO2 atmosphere at 37 °C. To induce
differentiation under adherent conditions, P19CL6 cells were plated at
a density of 3.7 × 105 cells in a 60-mm tissue
culture dish with the growth medium containing 1% Me2SO
(differentiation medium). The medium was changed every 2 days. Days of
differentiation were numbered consecutively with the 1st day of the
Me2SO treatment designated as day 0.
)/Myc-His B vector (Invitrogen) was used to make
Myc-tagged MIDORI protein with a 1-amino acid deletion of MIDORI at the
carboxyl terminus. COS cells were plated at a density of 4 × 104 cells in a 35-mm tissue culture dish on the day before
transfection. The constructed plasmids were transiently transfected
into COS cells by the calcium phosphate method and stained
immunochemically on the next day. The cells were fixed in 3%
paraformaldehyde, phosphate-buffered saline and subsequently incubated
with 50 mM ammonium chloride, 0.2% Triton X-100,
and 10% fetal bovine serum. Corresponding to the transfected plasmids,
either 500× diluted rabbit anti-HA polyclonal antibody or 20× diluted
mouse anti-Myc antibody was mounted as the first antibody. After
washing, either 200× diluted fluorescein
isothiocyanate-conjugated goat anti-rabbit IgG antibody or 50×
diluted rhodamine-conjugated goat anti-mouse IgG antibody was mounted
as the second antibody.
promoter and a neomycin
resistance gene, and the resultant genes were transfected into P19CL6
cells by the calcium phosphate method, respectively. Stable
transfectants were selected with 600 µg of neomycin (G418)/ml.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (97K):
[in a new window]
Fig. 1.
Differential mRNA display of
undifferentiated and differentiated P19CL6 cells. RNA was
extracted from undifferentiated P19CL6 cells (designated day 0) and
cells harvested 6 days after the Me2SO treatment
(designated day 6), respectively. Reverse transcriptase-polymerase
chain reaction with provided primers was carried out, and both samples
were electrophoresed. The band present in day 6 and absent in day 0 (arrow, 5A1) was cut out, eluted, and reamplified. The
primers used for reverse transcriptase-polymerase chain reaction are
shown at the top of the lane. 0, P19CL6 day 0;
6, P19CL6 day 6.

View larger version (59K):
[in a new window]
Fig. 2.
Midori expression in P19CL6 and in mice.
A, Northern blot analysis using the 5A1 fragment as a probe
revealed that the single ~6.4-kilobase pair band was not detected in
undifferentiated P19CL6 but was present abundantly on day 4 and
day 6 of differentiation and was weakly detected thereafter. We
designated the gene represented by 5A1 as Midori
(arrow). B and C, the expression of
Midori in vivo was restricted to the heart of fetal mice
(B) and to the heart and skeletal muscle of adult mice
(C) among the many organs examined. B, brain;
H, heart; K, kidney; Li, liver;
Lu, lung; C, P19CL6 day 6; I,
intestine; Sk, skeletal muscle; Sp, spleen;
St, stomach; T, testis.





View larger version (298K):
[in a new window]
Fig. 3.
cDNA and deduced amino acid sequence of
Midori. A conserved Kozak translation initiation
sequence, a polyadenylation signal, and an ATP/GTP-binding site motif
are shown in bold. Two Ig-like C2-type domains are
boxed. Nuclear localization signals are
underlined. A proline/alanine-rich region is indicated by a
dotted underline. A Kringle-like domain is indicated by a
broken underline.

View larger version (82K):
[in a new window]
Fig. 4.
Whole mount in situ
hybridization of Midori in mouse embryo.
Embryonic mice of 7.5-10.5 dpc were prepared and hybridized with
Midori sense, Midori antisense, and MLC2v
antisense cRNA probes. Midori expression was observed in the
cardiac crescent of mouse at 7.5 dpc and continued through 10.5 dpc. It
was localized within the heart during the period we have
examined.

View larger version (106K):
[in a new window]
Fig. 5.
Midori expression in transfected COS
cells. Two kinds of expression vectors encoding epitope-tagged
cDNA of Midori were transiently transfected into COS
cells. These cells were immunochemically stained, suggesting that both
HA- and Myc-tagged MIDORI proteins were localized in the nucleus.

View larger version (81K):
[in a new window]
Fig. 6.
Isolation of P19CL6-derived cells
overexpressing the sense or antisense Midori
transcripts. Three independent P19CL6-derived cell lines
overexpressing antisense Midori and five lines
overexpressing Midori were isolated, and two lines of
each group are shown. Endogenous Midori (arrow)
was expressed more abundantly than exogenous Midori (two
large arrowheads) in both of the sense
Midori-overexpressing cell lines (S1 and S2) without
Me2SO treatment, whereas endogenous Midori was
not detected in any antisense cell lines (A1 and A2).

View larger version (73K):
[in a new window]
Fig. 7.
Morphological and phenotypic changes observed
in the differentiated cell lines. Parental P19CL6 and the
transfectants overexpressing either antisense or sense
Midori transcripts were differentiated with
Me2SO. A, on day 11 of differentiation,
phase-contrast photomicrographs of live cultures showed that the
Midori sense clone (S1) more efficiently differentiated into
beating cardiomyocytes than did parental P19CL6 cells, whereas
antisense clones (A1 and A2) less efficiently differentiated. Highly
aggregated cells (arrowheads) appeared in wild type or more
often in the antisense clones and did not beat at all. B,
each cell line was double-stained with anti-sarcomeric MHC antibody
(MF20) and Hoechst dye on day 8 of differentiation. MF20-positive cells
are shown in red. In A1, many more aggregations
(arrowheads) were seen than in any other cell lines. In
contrast, many more MF20-positive cells were observed in S1 than in
parental P19CL6 cells, whereas less cells survived in S1 than in wild
type because of the extensive cell death during differentiation.
C, Western blot analysis of MHC was performed on day 14.5 of
differentiation. The bands corresponding to MHC are indicated by an
arrow. The amount of the protein was less in A1 than in
P19CL6, whereas more protein was detected in S1 than P19CL6.
P, positive control; CL6, P19CL6.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Komuro, I.,
and Izumo, S.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8145-8149
2.
Lints, T. J.,
Parsons, L. M.,
Hartley, L.,
Lyons, I.,
and Harvey, R. P.
(1993)
Genes Dev.
119,
419-431
3.
Bodmer, R.
(1993)
Development
118,
719-729
4.
Lyons, I.,
Parsons, L. M.,
Hartley, L.,
Li, R.,
Andrews, J. E.,
Robb, L.,
and Harvey, R. P.
(1995)
Genes Dev.
9,
1654-1666
5.
Schott, J. J.,
Benson, D. W.,
Basson, C. T.,
Pease, W.,
Silberbach, G. M.,
Moak, J. P.,
Maron, B. J.,
Seidman, C. E.,
and Seidman, J. G.
(1998)
Science
281,
108-111
6.
Benson, D. W.,
Silberbach, G. M.,
Kavanaugh-McHugh, A.,
Cottrill, C.,
Zhang, Y.,
Riggs, S.,
Smalls, O.,
Johnson, M. C.,
Watson, M. S.,
Seidman, J. G.,
Seidman, C. E.,
Plowden, J.,
and Kugler, J. D.
(1999)
J. Clin. Invest.
104,
1567-1573
7.
Hosoda, T.,
Komuro, I.,
Shiojima, I.,
Hiroi, Y.,
Harada, M.,
Murakawa, Y.,
Hirata, Y.,
and Yazaki, Y.
(1999)
Jpn. Circ. J.
63,
425-426
8.
Kuo, C. T.,
Morrisey, E. E.,
Anandappa, R.,
Sigrist, K.,
Lu, M. M.,
Parmasek, M. S.,
Soudais, C.,
and Leiden, J. M.
(1997)
Genes Dev.
11,
1048-1056
9.
Molkentin, J. D.,
Lin, Q.,
Duncan, S. A.,
and Olson, E. N.
(1997)
Genes Dev.
11,
1061-1072
10.
Lin, Q.,
Schwarz, J.,
Bucana, C.,
and Olson, E. N.
(1997)
Science
276,
1404-1407
11.
Grepin, C.,
Robitaille, L.,
Antakly, T.,
and Nemer, M.
(1995)
Mol. Cell. Biol.
15,
4095-4102
12.
Grepin, C.,
Nemer, G.,
and Nemer, M.
(1997)
Development
124,
2387-2395
13.
Monzen, K.,
Shiojima, I.,
Hiroi, Y.,
Kudoh, S.,
Oka, T.,
Takimoto, E.,
Hayashi, D.,
Hosoda, T.,
Habara-Ohkubo, A.,
Nakaoka, T.,
Fujita, T.,
Yazaki, Y.,
and Komuro, I.
(1999)
Mol. Cell. Biol.
19,
7096-7105
14.
Wu, X.,
Golden, K.,
and Bodmer, R.
(1995)
Dev. Biol.
169,
619-628
15.
Sugi, Y.,
Sasse, J.,
and Lough, J.
(1993)
Dev. Biol.
157,
28-37
16.
Mima, T.,
Ueno, H.,
Fischman, D. A.,
Williams, L. T.,
and Mikawa, T.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
467-471
17.
Lough, J.,
Barron, M.,
Brogley, M.,
Sugi, Y.,
Bolender, D. L.,
and Zhu, X.
(1996)
Dev. Biol.
178,
198-202
18.
Habara-Ohkubo, A.
(1996)
Cell Struct. Funct.
21,
101-110
19.
McBurney, M. W.,
Jones-Villeneuve, E. M.,
Edwards, M. K.,
and Anderson, P. J.
(1982)
Nature
299,
165-167
20.
Edwards, M. K.,
Harris, J. F.,
and McBurney, M. W.
(1983)
Mol. Cell. Biol.
3,
2280-2286
21.
Liang, P.,
and Pardee, A. B.
(1992)
Science
257,
967-971
22.
Bush, E. W.,
Taft, C. S.,
Meixell, G. E.,
and Perryman, M. B.
(1996)
J. Biol. Chem.
271,
548-552
23.
Dietz, U. H.,
and Sandell, L. J.
(1996)
J. Biol. Chem.
271,
3311-3316
24.
Miyazaki, T.,
Kanou, Y.,
Murata, Y.,
Ohmori, S.,
Niwa, T.,
Maeda, K.,
Yamamura, H.,
and Seo, H.
(1996)
J. Biol. Chem.
271,
14567-14571
25.
Wang, X.,
Yue, T. L.,
Ohlstein, E. H.,
Sung, C. P.,
and Feuerstein, G. Z.
(1996)
J. Biol. Chem.
271,
24286-24293
26.
Kozak, M.
(1991)
J. Cell Biol.
115,
887-903
27.
Venot, C.,
Maratrat, M.,
Dureuil, C.,
Conseiller, E.,
Bracco, L.,
and Debussche, L.
(1998)
EMBO J.
17,
4668-4679
28.
Iyemere, V. P.,
Davies, N. H.,
and Brownlee, G. G.
(1988)
Nucleic Acids Res.
26,
2098-2104
29.
Davis-Smyth, T.,
Chen, H.,
Park, J.,
Presta, L. G.,
and Ferrara, N.
(1996)
EMBO J.
15,
4919-4927
30.
Davis-Smyth, T.,
Presta, L. G.,
and Ferrara, N.
(1998)
J. Biol. Chem.
273,
3216-3222
31.
Herley, M. T., Yu, Y.,
Whitney, R. G.,
and Sato, J. D.
(1999)
Biochem. Biophys. Res. Commun.
262,
731-738
32.
Park, M.,
and Lee, S. T.
(1999)
Biochem. Biophys. Res. Commun.
264,
730-734
33.
Mahadevan, D., Yu, J. C.,
Saldanha, J. W.,
Thanki, N.,
McPhie, P.,
Uren, A.,
LaRochelle, W. J.,
and Heidaran, M. A.
(1995)
J. Biol. Chem.
270,
27595-27600
34.
Lokker, N. A.,
O'Hare, J. P.,
Barsoumian, A.,
Tomlinson, J. E.,
Ramakrishnan, V.,
Fretto, L. J.,
and Giese, N. A.
(1997)
J. Biol. Chem.
272,
33037-33044
35.
Chan, A. M.,
Rubin, J. S.,
Bottaro, D. P.,
Hirschfield, D. W.,
Chedid, M.,
and Aaronson, S. A.
(1991)
Science
254,
1382-1385
36.
Cioce, V.,
Csaky, K. G.,
Chan, A. M. L.,
Bottaro, D. P.,
Taylor, W. G.,
Jensen, R.,
Aaronson, S. A.,
and Rubin, J. S.
(1996)
J. Biol. Chem.
271,
13110-13115
37.
Chirgadze, D. Y.,
Hepple, J.,
Byrd, R. A.,
Sowdhamini, R.,
Blundell, T. L.,
and Gherardi, E.
(1998)
FEBS Lett.
430,
126-129
38.
Chirgadze, D. Y.,
Hepple, J. P.,
Zhou, H.,
Byrd, R. A.,
Blundell, T. L.,
and Gherardi, E.
(1999)
Nat. Struct. Biol.
6,
72-79
39.
Nagase, T.,
Kikuno, R.,
Ishikawa, K.,
Hirosawa, M.,
and Ohara, O.
(2000)
DNA Res.
7,
65-73
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
V. Betapudi, C. Mason, L. Licate, and T. T. Egelhoff Identification and Characterization of a Novel {alpha}-Kinase with a von Willebrand Factor A-like Motif Localized to the Contractile Vacuole and Golgi Complex in Dictyostelium discoideum Mol. Biol. Cell, May 1, 2005; 16(5): 2248 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A.G. van der Heyden and L. H.K. Defize Twenty one years of P19 cells: what an embryonal carcinoma cell line taught us about cardiomyocyte differentiation Cardiovasc Res, May 1, 2003; 58(2): 292 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Goldenthal and J. Marin-Garcia Stem cells and cardiac disorders: an appraisal Cardiovasc Res, May 1, 2003; 58(2): 369 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Mangi, S. B. Glueck, and R. E. Pratt Getting to the heart of the matter: Focus on "Microarray analysis of global changes in gene expression during cardiac myocyte differentiation" Physiol Genomics, June 3, 2002; 9(3): 131 - 133. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |